Blueprint Medicines (NASDAQ:BPMC) reported Q1 2018 earnings this Morning, coming in at ($1.29) per share, missing Wall Street’s estimates of ($1.15) per Share. Revenue for the quarter came in at $0.95 million missing the streets estimates of $2.82 million Recent Insider Trading for Blueprint Medicines (NASDAQ:BPMC)
- On 3/19/2018 George Demetri, Director, sold 5,492 with an average share price of $100.09 per share and the total transaction amounting to $549,694.28.
- On 3/15/2018 Marion Dorsch, Insider, sold 2,300 with an average share price of $100.07 per share and the total transaction amounting to $230,161.00.
- On 3/2/2018 Jeffrey W Albers, CEO, sold 20,000 with an average share price of $92.57 per share and the total transaction amounting to $1,851,400.00.
- On 2/28/2018 Nicholas Lydon, Director, sold 25,000 with an average share price of $87.89 per share and the total transaction amounting to $2,197,250.00.
- On 2/14/2018 Daniel Lynch, Director, sold 12,500 with an average share price of $80.42 per share and the total transaction amounting to $1,005,250.00.
- On 2/12/2018 Daniel Lynch, Director, sold 17,500 with an average share price of $74.84 per share and the total transaction amounting to $1,309,700.00.
Dividend History for Blueprint Medicines (NASDAQ:BPMC)
Recent Trading for Blueprint Medicines (NASDAQ:BPMC) Shares of Blueprint Medicines closed the previous trading session at 79.50 down -0.14 0.18% with 79.0 shares trading hands.